Pregled bibliografske jedinice broj: 91282
Encapsulation of new biologically active peptides into liposomes and their immunoadjuvant effect
Encapsulation of new biologically active peptides into liposomes and their immunoadjuvant effect // Peptides 2002, Proceedings of the Twenty-Seventh European Peptide Symposium / Benedetti, Ettore ; Pedone, Carlo (ur.).
Napulj: Edizioni Ziino, 2002. str. 490-491 (poster, međunarodna recenzija, cjeloviti rad (in extenso), znanstveni)
CROSBI ID: 91282 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Encapsulation of new biologically active peptides into liposomes and their immunoadjuvant effect
Autori
Frkanec, Ruža ; Tomašić, Jelka ; Vranešić, Branka ; Halassy Špoljar, Beata ; Krstanović, Marina
Vrsta, podvrsta i kategorija rada
Radovi u zbornicima skupova, cjeloviti rad (in extenso), znanstveni
Izvornik
Peptides 2002, Proceedings of the Twenty-Seventh European Peptide Symposium
/ Benedetti, Ettore ; Pedone, Carlo - Napulj : Edizioni Ziino, 2002, 490-491
Skup
Twenty-Seventh European Peptides Symposium
Mjesto i datum
Sorrento, Italija, 31.08.2002. - 06.09.2002
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
liposomes; peptidoglycan monomer; adamantyltripeptides; adjuvants
Sažetak
We have been examining the encapsulation of the new immunomodulators of peptidoglycan structure and synthetic adamantyltripeptides into the liposomes with the aim to possibly increase and optimize their therapeutic efficacy. Our studies concern two groups of immunomodulators: a) peptidoglycan monomer (PGM, GlcNAc-MurNAc-L-Ala-D-isoGln-mesoA2pm(eNH2)-D-Ala-D-Ala) and b) synthetic adamantyltripeptides (D- and L-(adamant-2-yl)-Gly-L-Ala-D-isoGln) comprising a part of peptidoglycan structure. All mentioned compounds were shown previously to exhibit immunostimulating activity1, 2. The immunostimulators tested were incorporated in large multilamellar negatively charged vesicles using egg lecithin and synthetic dipalmitoyl phosphatidylcholine (DPPC). The entrapment of tested compounds and the stability of the respective preparations were followed in two ways: by the use of 14C-labelled peptidoglycans or by HPLC. The immunoadjuvant activity was tested in vivo, in mice, using ovalbumin (OVA) as an antigen. The production of OVA-specific antibodies was monitored by ELISA. In comparison to the nonentrapped tested compounds the encapsulated preparations showed the better anti-OVA antibody production. Hence, incorporation of immunoadjuvants into liposomes improved their adjuvant activity. In conclusion, liposomes containing immunoadjuvants were prepared, quantity of incorporated material determined and the improved adjuvant effect of immunoadjuvants was demonstrated. 1. J. Tomašić, I. Hanzl-Dujmović, B. Špoljar, B. Vranešić, M. Šantak, A. Jovičić, Vaccine 8 (2000) 1236-1243. 2. B. Vranešić, J. Tomašić, S. Smerdel, D. Kantoci, F. Benedetti, Helv. Chim. Acta 76 (1993) 1752-1758.
Izvorni jezik
Engleski
Znanstvena područja
Kemija, Biologija, Temeljne medicinske znanosti
POVEZANOST RADA
Projekti:
0021002
Ustanove:
Imunološki zavod d.d.
Profili:
Branka Vranešić
(autor)
Jelka Tomašić
(autor)
Beata Halassy
(autor)
Marina Krstanović
(autor)
Ruža Frkanec
(autor)